Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $64.9 million.

  • Spyre Therapeutics' Cash & Equivalents fell 933.64% to $64.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.9 million, marking a year-over-year decrease of 933.64%. This contributed to the annual value of $89.4 million for FY2024, which is 5265.94% down from last year.
  • Latest data reveals that Spyre Therapeutics reported Cash & Equivalents of $64.9 million as of Q3 2025, which was down 933.64% from $81.7 million recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Cash & Equivalents registered a high of $235.4 million during Q2 2023, and its lowest value of $14.6 million during Q1 2022.
  • Its 5-year average for Cash & Equivalents is $76.8 million, with a median of $48.5 million in 2025.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 8319.33% in 2021, then surged by 54566.58% in 2024.
  • Spyre Therapeutics' Cash & Equivalents (Quarter) stood at $15.1 million in 2021, then soared by 130.24% to $34.9 million in 2022, then skyrocketed by 441.82% to $188.9 million in 2023, then tumbled by 52.66% to $89.4 million in 2024, then dropped by 27.43% to $64.9 million in 2025.
  • Its last three reported values are $64.9 million in Q3 2025, $81.7 million for Q2 2025, and $48.5 million during Q1 2025.